Market Place
Sourcing Support
Gilead’s Livdelzi Shows Sustained Efficacy in Biliary Cholangitis
15 Nov 2024 //
BUSINESSWIRE
Gilead to lay off 72 staffers, shutter Seattle R&D office
14 Nov 2024 //
FIERCE BIOTECH
Gilead Presents PURPOSE 2 Data on Lenacapavir for HIV Prevention
13 Nov 2024 //
BUSINESSWIRE
Gilead Prices $3.5 Billion of Senior Unsecured Notes
13 Nov 2024 //
BUSINESSWIRE
Gilead Presents Research on Broad HIV Treatment Portfolio
12 Nov 2024 //
BUSINESSWIRE
Gilead`s CAR-T sales stagnate as Trodelvy takes another write-off
11 Nov 2024 //
FIERCE PHARMA
Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged
11 Nov 2024 //
FIERCE PHARMA
Gilead Sciences to Present at Upcoming Investor Engagements
08 Nov 2024 //
BUSINESSWIRE
Gilead Presents Data & Extends HIV Leadership at HIV Glasgow
07 Nov 2024 //
BUSINESSWIRE
Gilead Q3 results beat Wall Street estimates, raises outlook
07 Nov 2024 //
REUTERS
Gilead Sciences Announces Q3 2024 Financial Results
06 Nov 2024 //
BUSINESSWIRE
Kite to Present CAR T-Cell Therapy Data at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
ASH: Gilead-Arcellx data build CAR-T`s case in advanced myeloma
05 Nov 2024 //
FIERCE BIOTECH
Gilead Oncology Grant Supports 22 U.S. Breast Cancer Organizations
31 Oct 2024 //
ACCESSWIRE
Gilead To Present Research At AASLD Meeting 2024
22 Oct 2024 //
BUSINESSWIRE
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
22 Oct 2024 //
FIERCE BIOTECH
Gilead withdraws bladder cancer drug in US after failed trial
19 Oct 2024 //
REUTERS
GSK bolsters case for long-acting HIV PrEP drug Apretude
16 Oct 2024 //
FIERCE PHARMA
Gilead gives up on $15M MASH bet after mulling preclinical data
11 Oct 2024 //
FIERCE BIOTECH
Gilead To Present Late-Breaking Data At IDWeek 2024
09 Oct 2024 //
BUSINESSWIRE
Gilead To Release Q3 2024 Results November 6
09 Oct 2024 //
BUSINESSWIRE
Enforcement Report - Week of October 9, 2024
09 Oct 2024 //
FDA
Gilead: Report Shows Countries Must Do More To End HIV Epidemic
08 Oct 2024 //
ACCESSWIRE
Gilead Presents Data From PURPOSE 2 Trial At HIV Conference
07 Oct 2024 //
BUSINESSWIRE
Emcure Pharma partners with Gilead Sciences to produce HIV drug
04 Oct 2024 //
PRESS RELEASE
Gilead To Donate Remdesivir For Emergency Use Against Marburg
03 Oct 2024 //
REUTERS
Dr Reddy`s sign voluntary licenses with Gilead for HIV drug
02 Oct 2024 //
PRESS RELEASE
Gilead inks licensing deals to boost lenacapivir access
02 Oct 2024 //
FIERCE PHARMA
Gilead recalls 1 lot of Veklury due to glass particle in vial
26 Sep 2024 //
FIERCE PHARMA
Gilead leads Asian patient groups’ drugmaker reputation rankings
25 Sep 2024 //
FIERCE PHARMA
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
24 Sep 2024 //
GLOBENEWSWIRE
Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury
23 Sep 2024 //
FDA
Gilead Taps Yuhan To Supply HIV Drug Ingredients In $81M Deal
20 Sep 2024 //
FIERCE PHARMA
Gilead`s Kite Exits China Joint Venture With Fosun
19 Sep 2024 //
FIERCE PHARMA
Gilead`s Long-Acting PrEP Drug Wins Phase 3 Trial, Eyes 2025 Launch
13 Sep 2024 //
FIERCE PHARMA
Helping End HIV - Gilead Sciences
12 Sep 2024 //
ACCESSWIRE
Gilead`s Lenacapavir Shows 96% HIV Infection Reduction In Phase 3
12 Sep 2024 //
BUSINESSWIRE
OmRx Oncology Launches To Advance Oral Checkpoint Inhibitor
12 Sep 2024 //
BUSINESSWIRE
Seramount Ranks Gilead In Leading Inclusion Index Company
10 Sep 2024 //
ACCESSWIRE
Gilead And Genesis Announce Therapeutic Collaboration
10 Sep 2024 //
BUSINESSWIRE
Gilead inks $35M collab with AI drug discovery outfit Genesis
10 Sep 2024 //
FIERCE BIOTECH
Gilead`s Trodelvy Triplet Underwhelms But Supports Phase 3 Lung Design
09 Sep 2024 //
FIERCE PHARMA
Gilead Sciences: Rare Liver Disease Story: Maria`s Journey
06 Sep 2024 //
ACCESSWIRE
Gilead to Present New Trodelvy® Data at IASLC 2024 World Lung Cancer Conference
05 Sep 2024 //
BUSINESSWIRE
Gilead Sciences to Present at Upcoming Investor Conferences
21 Aug 2024 //
BUSINESSWIRE
Pantherv Rare Partners With Gilead For Distribution Of LIVDELZI®
16 Aug 2024 //
PR NEWSWIRE
FDA approval of Livdelzi, Gilead launches an inflammatory drug for first time
16 Aug 2024 //
FIERCE PHARMA
Gilead pays J&J $320M to exit licensing deal for seladelpar
09 Aug 2024 //
FIERCE BIOTECH
Gilead looks to `redefine` HIV PrEP market of long-acting Sunlenca
09 Aug 2024 //
FIERCE PHARMA
Gilead quarterly profit beats Street estimates, revenue up 5%
08 Aug 2024 //
REUTERS
Gilead shells out $320M to J&J to buy out rare liver disease drug royalties
08 Aug 2024 //
ENDPTS
Closing the HIV Diagnosis Gap in Germany with Gilead Sciences
08 Aug 2024 //
ACCESSWIRE
Gilead Sciences Announces Second Quarter 2024 Financial Results
08 Aug 2024 //
BUSINESSWIRE
HIV Research Progress: `Next Berlin Patient` And PrEP`s 100% Efficacy
02 Aug 2024 //
FIERCE PHARMA
3 Big Pharma companies, 33 phase 3 trials: The race to supremacy in an ADC field
02 Aug 2024 //
FIERCE PHARMA
FDA Clears Compugen`s IND For COM503 In Solid Tumors Treatment
29 Jul 2024 //
PR NEWSWIRE
Gilead Presents Data On HIV Treatment Portfolio And Pipeline
25 Jul 2024 //
BUSINESSWIRE
Gilead Presents Full Results Of Lenacapavir For HIV Prevention At AIDS 2024
24 Jul 2024 //
BUSINESSWIRE
GSK’s Dovato matches Gilead’s HIV juggernaut Biktarvy in Spanish trial
24 Jul 2024 //
FIERCE PHARMA
UN urges Gilead to `make history` with game-changing HIV drug
22 Jul 2024 //
ECONOMICTIMES
